Alendronate for the treatment of osteoporosis in men

Article Abstract:

In a study of 241 men with osteoporosis and aged 31 to 87 years, alendronate treatment improved bone mineral density of the spine, the hip, and total body. The bone mineral density increased by 7.1%, 2.5% and 2.0% in the lumbar spine, femoral neck, and the total body respectively. The treatment also reduced significantly the vertebral fracture occurrence.

Italy, Australia, Canada, Austria, Poland, Belgium, Health aspects, Statistical Data Included, Bones, Bone density, Men, Men's health, Vertebrae, Spinal fractures

---

Decimal point-osteoporosis therapy at the 10-year mark

Article Abstract:

With the worldwide spread of the osteoporosis pandemic, researchers have developed the first orally diophosphonate in the United States called Alendronate for the treatment of osteoporosis. Two groups of post-menopausal women were given alendronate at a dose of 5 mg and 10 mg daily to exemplify the effectiveness of the drug and it was found that the bone turnover was reduced by more than 50 per cent in women who received continuous alendronate therapy.

Science & research, Research, Drug testing

---

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis

Article Abstract:

Alendronate may be effective in treating postmenopausal osteoporosis by increasing bone mass and decreasing the occurrence of spinal bone fractures, spinal deformities, and height loss. For three years, 881 postmenopausal women with osteoporosis received 500 milligrams (mg) of calcium a day plus either a placebo or alendronate. Of the 526 women who received alendronate, some received 5 mg/day, some 10 mg/day, and some 20 mg/day for two years followed by 5 mg/day for the third year. The 10 mg/day dose appeared to be the optimal dose. The bone mineral density increased in the alendronate groups and decreased in the placebo group. New fractures of vertebra occurred in 6.2% of the women receiving placebos and 3.2% of the women receiving alendronate. Spinal deformations increased by 41% in the placebo group and 33% in the alendronate group. The average height loss was 4.6 millimeters in the placebo group and 3.0 millimeters in the alendronate group. Side effects in both groups included abdominal pain, muscle pain, and nausea.

Evaluation, Drug therapy, Diphosphonates

Similar abstracts:

• Abstracts: Effect of Estrogen on Brain Activation Patterns in Postmenopausal Women During Working Memory Tasks. Estrogen and Alzheimer Disease Plausible Theory, Negative Clinical Trial
• Abstracts: Assessment of the effect of oral corticosteroids on bone mineral density in systemic lupus erythematosus: a preliminary study with dual energy x ray absorptiometry
• Abstracts: Effects of hormone replacement therapy on endometrial histology in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial
• Abstracts: Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men. Do Statins Prevent Both Cardiovascular Disease and Fracture?
• Abstracts: The failed suppression of serum estradiol level by gonadotropin-releasing hormone agonist in a case of pelvic endometriosis

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.